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Assessing the effect of interventions for
axial spondyloarthritis according to the
endorsed ASAS/OMERACT core outcome
set: a meta-research study of trials included
in Cochrane reviews
Rikke A. Andreasen1,2 , Lars E. Kristensen2, Xenofon Baraliakos3, Vibeke Strand4, Philip J. Mease5, Maarten de Wit6,
Torkell Ellingsen7, Inger Marie J. Hansen1, Jamie Kirkham8, George A. Wells9, Peter Tugwell10, Lara Maxwell10,
Maarten Boers11, Kenneth Egstrup12 and Robin Christensen2,7*
Abstract
The Assessment of SpondyloArthritis international Society (ASAS) has defined core sets for (i) symptom-modifying
anti-rheumatic drugs (SM-ARD), (ii) clinical record keeping, and (iii) disease-controlling anti-rheumatic therapy (DC-
ART). These include the following domains for all three core sets: “physical function,” “pain,” “spinal mobility,” “spinal
stiffness,” and “patient’s global assessment” (PGA). The core set for clinical record keeping further includes the
domains “peripheral joints/entheses” and “acute phase reactants,” and the core set for DC-ART further includes the
domains “fatigue” and “spine radiographs/hip radiographs.” The Outcome Measures in Rheumatology (OMERACT)
endorsed the core sets in 1998.
Using empirical evidence from axSpA trials, we investigated the efficacy (i.e., net benefit) according to the ASAS/
OMERACT core outcome set for axSpA across all interventions tested in trials included in subsequent Cochrane
reviews. For all continuous scales, we combined data using the standardized mean difference (SMD) to meta-
analyze outcomes involving the same domains. Also, through meta-regression analysis, we examined the effect of
the separate SMD measures (independent variables) on the primary endpoint (log [OR], dependent variable) across
all trials.
Based on 11 eligible Cochrane reviews, from these, 85 articles were screened; we included 43 trials with 63
randomized comparisons. Mean (SD) number of ASAS/OMERACT core outcome domains measured for SM-ARD/
physical therapy trials was 4.2 (1.7). Six trials assessed all proposed domains. Mean (SD) for number of core outcome
domains for DC-ART trials was 5.8 (1.7). No trials assessed all nine domains. Eight trials (16%) were judged to have
(Continued on next page)
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inadequate (i.e., high risk of) selective outcome reporting bias. The most responsible core domains for achieving
success in meeting the primary objective per trial were pain, OR (95% CI) 5.19 (2.28, 11.77), and PGA, OR (95% CI)
1.87 (1.14, 3.07). In conclusion, selective outcome reporting (and “missing data”) should be reduced by encouraging
the use of the endorsed ASAS/OMERACT outcome domains in clinical trials. Overall outcome reporting was good
for SM-ARD/physical therapy trials and poor for DC-ART trials. Our findings suggest that both PGA and pain provide
a valuable holistic construct for the assessment of improvement beyond more objective measures of spinal
inflammation.
Keywords: Axial spondyloarthritis, Ankylosing spondylitis, Core outcome set, Meta-analysis
Introduction
Since 1992, the Outcome Measures in Rheumatology
(OMERACT) consensus initiative has successfully devel-
oped core—or minimum—sets for many rheumatologic
conditions [1]. A “core outcome set” (COS) represents
which outcome domains (i.e., constructs or concepts
[what to measure]) and outcome measurements (i.e.,
how to measure]) to apply in RCTs [2].
ASAS has aimed to bring evidence-based unity to
the multitude of assessments in the field of axial
spondyloarthritis (axSpA). Currently, ASAS’s scope in-
cludes the entire spectrum of SpA [3]. axSpA com-
prises two subcategories based on the presence of
structural changes in the sacroiliac joints: radio-
graphic (r-) axSpA, implying the fulfillment of the
modified New York criteria, and non-radiographic
(nr) axSpA.
ASAS has selected a set of core outcome domains
to include among a set of standardized measures in
clinical trials, which is defined by the following sce-
narios: (i) symptom-modifying anti-rheumatic drugs
(SM-ARD)/physiotherapy, (ii) clinical record keeping
for studies, and (iii) disease-controlling anti-rheumatic
therapy (DC-ART) (Fig. 1). The selected domains to
include as standardized outcomes in RCTs for all
three scenarios include the following: “physical func-
tion,” “pain,” “spinal mobility,” “spinal stiffness,” and
“patient’s global assessment” (PGA). The core set for
clinical record keeping further includes the domains
“peripheral joints/entheses” and “acute phase reac-
tants,” and the core set for DC-ART further includes
the domains “fatigue” and “spine and hip radiographs”
[4]. ASAS core outcome domain sets were endorsed
by OMERACT in 1998 [5].
Although composite outcomes seem an attractive
method to increase statistical power (e.g., BASDAI 50
response), they can mask the effect of (or absence of)
the individual domains of treatment. This study there-
fore sets out to assess the effect of interventions for
axSpA according to each core domain in the existing
COS, as well as its association with the primary statis-
tical outcome in the individual trials.
Main text
Materials and methods
We conducted a meta-epidemiological study by evalu-
ating axSpA trials included in Cochrane reviews (i.e.,
Cochrane Musculoskeletal Review Group). Study se-
lection, assessment of eligibility criteria, data extrac-
tion, and statistical analyses were performed based on
a pre-specified protocol. In accordance with current
methodology, the protocol is available (Supplement A)
and registered on PROSPERO (CRD42018091257).
The study conforms to the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines for reporting systematic reviews and meta-
analyses [6, 7].
Literature search
A systematic search was done on May 1, 2018, to
identify all Cochrane reviews that reported interven-
tions for the management of axSpA. Two reviewers
(RAA and RC) searched directly in the Cochrane
Database of Systematic Reviews, where eligible trials
were identified from published Cochrane reviews (i.e.,
meta-analyses) after a thorough search, using the fol-
lowing terms: (ankylosing spondylitis OR bechterew
disease OR ankylosing spondylarthritides OR axial
spondyloarthritis OR axial spondyloarthritides). The
most recent version of the Cochrane review was used.
Unlike what was pre-specified in PROSPERO, for
feasibility, we used the Cochrane Database of System-
atic Reviews directly rather than PubMed, since this
meta-research study’s eligibility criteria state that only
trials included in Cochrane reviews would be consid-
ered for eligibility.
Eligibility criteria
Cochrane reviews that incorporated RCTs in patients
with axSpA were included in our study. Only reviews
with superiority trials were considered eligible. All re-
ports for each RCT included in eligible reviews were ob-
tained for evaluation. Non-RCTs and trials without full
publications were excluded.
Andreasen et al. Arthritis Research & Therapy          (2020) 22:177 Page 2 of 16
Risk of bias in individual studies (internal validity)
The risk of bias (RoB) within each study was assessed
using the domains of the RoB tool, as recommended by
the Cochrane Collaboration [8]. The bias domains in-
cluded selection bias (methods for sequence generation
and allocation concealment), performance bias (blinding
of participants and personnel), attrition bias (incomplete
outcome data), and reporting bias (selective outcome
reporting). Each domain was rated as adequate, inad-
equate, or unclear risk of bias [9]. RAA completed all
the RoB assessments and applied the RoB that was in-
cluded and reported in the original Cochrane reviews as
a proxy for a second reviewer assessment.
Data extraction strategy
At trial level, the terms of extraction comprised information
about the first author, publication year, study duration, type
of intervention, and total number of patients randomized.
The domains that were collected included the following:
(i) physical function, (ii) pain, (iii) spinal mobility, (iv)
spinal stiffness, (v) fatigue, (vi) patient’s global assessment,
(vii) peripheral joints/entheses, (viii) acute phase reactants,
and (ix) spine and hip radiographs. Furthermore, at the in-
dividual trial level, we extracted data on how many partici-
pants achieved the stated primary outcome.
If data on more than one instrument was provided for
any domain, we extracted data on the scale highest on
the list proposed by ASAS/OMERACT [3, 4] (Supple-
ment B).
Trials with multiple intervention arms were treated as
individual trials, referred to as “randomized compari-
sons” (i.e., three-arm trials with two active interventions
generated two randomized comparisons with placebo).
However, the number of patients in the placebo groups
was divided by the number of active treatment arms,
thus adjusting the standard errors in order to avoid
double counting of patients [10].
Statistical analysis
Treatment effect sizes for all domains were expressed as
standardized mean differences (SMDs) [11]. Standard pair-
wise meta-analyses for the nine domains’ SMDs with the
corresponding 95% confidence interval (CI) were performed
with Review Manager (version 5.3). Negative SMD values
indicated a beneficial effect of the experimental intervention
(e.g., pain reduction) compared with control comparator; for
ease of interpretation, we used the following “rule of
thumb”: SMDs of more than 0.2 represents a small effect,
0.5 a moderate effect, and 0.8 a large effect [12].
We used standard random-effect meta-analysis as the
default option, whereas the fixed-effect analysis was applied
for the purpose of sensitivity [13]. We used the chi2 test
(Cochrane’s Q test) to assess heterogeneity and the I2
statistic to assess inconsistency [8, 13]. Anticipating
substantial heterogeneity, a pre-specified number of strati-
fied and meta-regression analyses were planned. We con-
ducted the following stratified analyses to examine the
influence of different subgroups—Pharmacological vs. Non-
Fig. 1 ASAS/OMERACT core domains for axSpA. Inner circle, core domains for SM-ARD/physical therapy; two inner circles, core domains for
clinical record keeping; all three circles, core domains for DC-ART. SM-ARD, symptom-modifying anti-rheumatic drug; DC-ART, disease-controlling
anti-rheumatic treatment
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pharmacological treatment, and Biologic vs. Other treat-
ment—on the effect of the interventions for all the core
outcomes. Only covariates that reduced the variation (de-
crease in the τ2 estimated as tau squared [T2]) seen in the
estimates across strata were considered potentially relevant.
In trials where the primary outcome was a composite out-
come, meta-regression was performed to investigate which
of the nine core domains (via the available SMDs) were best
associated with the primary composite endpoint of the indi-
vidual trials (log [ORi]). Meta-regression was performed in
a stepwise manner with the following three steps:
1. Each of the core domains was analyzed as the only
independent variable in a univariate meta-
regression analysis concerning the effect of the do-
mains on the odds ratio (OR) for achieving the pri-
mary endpoint. Arbitrarily, it was decided that
variables with a P value > 0.05 were excluded as po-
tential explanatory variables in step 3. The analyses
were based on all trials reporting the primary
endpoint.
2. The univariate meta-regression analysis mentioned
above was repeated, but only trials reporting all the
domains affecting the log [ORi] (P < 0.05) were in-
cluded in the analysis.
3. The explanatory core domains from step 1 (P <
0.05) were analyzed as the independent variables in
a multivariate meta-regression analysis.
These meta-regression analyses enabled us to explore
which core domains were best reflected in the composite
endpoint of axSpA and what is lost when we neglect
core domains by using only one composite outcome
endpoint.
Patient perspective
As part of the author team, MdW—an experienced pa-
tient research partner (PRP)—was consulted to review
and elaborate on the protocol and confirmed the im-
portance of the study from the patient’s perspective.
MdW was involved throughout the research process as a
scientific collaborator and voluntarily participated in the
process of designing and preparing the study protocol
and in interpreting results. Where feasible, we followed
the EULAR recommendations for PRPs [14].
Results
Study selection
The search was carried out directly in the Cochrane Li-
brary on May 01, 2018. As illustrated in Fig. 2, the
Fig. 2 Flow chart. M0, identified Cochrane reviews; M1, possible eligible reviews; M2, included reviews; K, trials from included Cochrane reviews, k*,
trials included in the evidence synthesis
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inclusion criteria identified twelve Cochrane reviews;
one review was excluded based on the title and abstract
[15]. Eleven reviews were thus retrieved for full-text
examination [16–26]. After full-text examination, we ex-
cluded another six reviews (three reviews did not include
axSpA trials [21–23]; two reviews were protocols only
[25, 26]; one review did not report results for axSpA sep-
arately [24]). A total of five Cochrane reviews [16–20]
with 85 possible trials were identified for inclusion. We
excluded 35 studies—3 were not RCTs and 32 were not
superiority trials—thus, 50 trials were found eligible for
the qualitative synthesis (for reference list of included
studies, see Supplement B). Of these 50 trials, 7 were
not included in the quantitative synthesis: 6 trials re-
ported most of the data as graphs, and data were not ex-
tracted [27–32], and one trial was excluded due to
language restriction (Chinese [33]). The 43 included
RCTs comprised a total of 63 comparisons. The inter-
ventions were categorized into three treatment groups:
non-pharmacological (NP) modalities, pharmacological
(P) modalities, and biological (B) modalities.
Study characteristics
The characteristics of the eligible trials are summarized
in Table 1.
Twenty-two trials (42%) used an adequate conceal-
ment of allocation and sequence generation (selection).
Twenty-seven trials (54%) were judged to have adequate
blinding of participants and caregivers (performance),
and 34 trials (68%) adequately addressed incomplete
outcome data (attrition). Eight trials [29, 34–40] (16%)
were unable to provide the data of all the pre-specified
outcomes, and we judged them at high risk of selective
outcome reporting bias.
Characteristics of the core outcome measurement set
The outcome matrix (Table 2) shows which core do-
mains were measured for each trial and by which
measurement instrument, differentiating between
those which were fully and partially reported. Overall
outcome reporting was good for SM-ARD/physical
therapy trials; mean (SD) number of ASAS/OMER-
ACT core outcome domains measured for SM-ARD/
physical therapy trials was 4.2 (1.7), and six trials
assessed all five proposed domains. Mean (SD) num-
ber of ASAS/OMERACT core outcome domains mea-
sured for DC-ART trials was 5.3 (1.8). No DC-ART
trial assessed all nine domains. The most commonly
measured domain was spinal mobility (88%) which
was assessed followed by pain (86%). Most studies
also included measures of physical function (78%),
spinal stiffness (76%), acute phase reactants (70%),
and patient’s global assessment (62%). The instru-
ments used to measure the domains varied widely
across trials. For the domain fatigue, only seven trials
(14%) had reported this measure separately. Spine ra-
diographs were also poorly represented (2%). None of
the trials reported hip radiographs.
Physical function
All meta-analyses are shown in Supplement B.
A total of 33 RCTs (43 comparisons, 4819 partici-
pants) were included in the meta-analysis. As pre-
sented in Table 3, the overall analysis of change in
physical function (PF) showed an SMD of − 0.50
(95% CI, − 0.61 to − 0.40), indicating moderate effect
in favor of participants receiving intervention com-
pared to participants receiving control. A high
between-study heterogeneity was observed, τ2 = 0.07,
with substantial inconsistency across studies (I2 =
64%). However, the fixed-effect analysis was in
agreement with the random-effect model, resulting
in a pooled SMD of − 0.53 (− 0.60 to − 0.47). The
stratified meta-analyses for PF did not result in a
significant reduction of τ2; type of intervention did
not seem to be an important factor to the inconsist-
ency observed across axSpA trials, when measuring
change in PF.
Pain
In total, thirty trials (41 intervention comparisons,
4877 participants) were included in the analysis.
Pooled analysis revealed statistically significant re-
duction in pain with an overall SMD of − 0.48 (−
0.66 to − 0.30), indicating moderate effect across all
interventions in axSpA trials. Between-study incon-
sistency was substantial (I2 = 62%). A large reduction
in heterogeneity was found in the “type of interven-
tion variable” [58] (i.e., non-pharmacological [58] vs.
pharmacological [P]), which in turn resulted in a
significant reduction in τ2 at 32%, supported by a
statistically highly significant P value (P < 0.001) for
interaction between NP and P. Trials with pharma-
cological interventions had a pooled SMD of − 0.64
(− 0.78 to − 0.49), whereas trials with NP interven-
tions had an overall SMD of 0.26 (− 0.20 to 0.72).
Spinal mobility
Forty-three trials (45 comparisons, 5091 participants)
were included in our meta-analysis. Pooled analysis re-
vealed a small improvement in spinal mobility (SM) with
an overall SMD of − 0.32 (− 0.48 to − 0.17). A high
between-study heterogeneity was observed, τ2 = 0.21,
with a large inconsistency across studies (I2 = 83%).
None of the subgroup analyses resulted in a significant
reduction in τ2.
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Table 1 Study characteristics and risk of bias assessment of included studies









Intervention Comparator Risk of bias* selection/
performance/attrition/
reporting
Dougados 1986 30 15 15 26 SSZ (P) PL A/A/A/A
Feltelius 1986 37 18 19 12 SSZ (P) PL U/U/A/A
Nissila 1988 85 43 42 26 SSZ (P) PL U/U/A/A
Davis 1989 30 15 15 12 SSZ (P) PL U/U/A/A
Kraag 1989 53 26 27 16 Supervised
training (NP)
SC U/U/I/A
Winkler 1989 63 31 32 24 SSZ (P) PL U/U/U/A
Corkill 1990 62 32 30 48 SSZ (P) PL A/A/I/A
Krajnc 1990 95 71 24 24 SSZ (P) PL U/U/A/A
Taylor 1991 40 20 20 52 SSZ (P) PL A/A/A/I




Kirwan 1993 89 44 45 156 SSZ (P) PL A/A/A/I
Dougados 1994 70 46 24 12 Ximoprofen 5
mg (P)
PL A/A/U/A
1994 73 49 24 34 Ximoprofen 10
mg (P)
PL A/A/U/A
1994 69 45 24 8 Ximoprofen 20
mg (P)
PL A/A/U/A
1994 74 50 24 6 Ximoprofen 30
mg (P)
PL A/A/U/A
Clegg 1996 264 131 133 36 SSZ (P) PL U/U/A/A








Dougados 1999 148 108 40 6 Piroxicam (P) PL U/U/A/A
1999 160 120 40 6 Meloxicam 15
mg (P)
PL U/U/A/A
1999 164 124 40 6 Meloxicam 22.5
mg (P)
PL U/U/A/A
Altan 2001 51 26 25 52 MTX (P) AC U/U/I/I
Dougados 2001 118 80 38 6 Celecoxib (P) PL U/U/U/A
2001 128 90 38 6 Ketoprofen (P) PL U/U/U/A
Van Tubergen 2001 120 80 40 3 Spa-exercise
therapy (NP)
AC A/A/I/A
Braun 2002 70 35 35 12 Infliximab (B) PL A/A/A/I
Gorman 2002 40 20 20 16 Etanercept (B) PL A/A/A/A
Roychowdhury 2002 30 14 16 24 MTX (P) PL U/U/A/A
Schmidt 2002 70 34 36 26 SSZ (P) PL U/U/U/A
Sweeney 2002 200 100 100 26 Supervised
training (NP)
SC U/U/I/A
Analay 2003 51 27 24 12 Supervised
training (NP)
SC A/A/I/A
Brandt 2003 33 16 17 6 Etanercept (B) PL A/A/A/I
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Spinal stiffness
In total, 25 trials (34 comparisons, 3658 partici-
pants) were included in the analysis. The overall ef-
fect size revealed substantive statistically significant
improvement in spinal stiffness, SMD of − 0.59 (−
0.74 to − 0.44), indicating moderate effect of all in-
terventions in axSpA trials. The heterogeneity was
large, τ2 = 0.14, with substantial inconsistency
Table 1 Study characteristics and risk of bias assessment of included studies (Continued)









Intervention Comparator Risk of bias* selection/
performance/attrition/
reporting
Davis 2003 277 138 139 24 Etanercept (B) PL A/A/A/A
Calin 2004 84 45 39 12 Etanercept (B) PL U/U/A/A
Gonzalez-
Lopez
2004 35 17 18 24 MTX (P) PL A/A/A/I
Codish 2005 28 14 14 12 Balneo therapy
(NP)
AC U/U/I/A
D’Las Penas 2005 40 20 20 16 Supervised
training (NP)
SC A/A/I/A
Lim 2005 50 25 25 8 Supervised
training (NP)
SC U/U/I/A
Marzo-Ortega 2005 42 28 14 30 Infliximab (B) PL A/A/U/A
Van der Heijde 2005 279 201 78 24 Infliximab (B) PL U/U/A/A
Van der Heijde 2005 134 103 31 6 Etoricoxib (P) PL A/A/A/A
2005 123 92 31 6 Etoricoxib (P) PL A/A/A/A
2005 130 99 31 6 Naproxen (P) PL A/A/A/A
Altan 2006 60 30 30 24 Balneo therapy
(NP)
AC U/U/I/A
Barkhuizen 2006 189 137 52 12 Celecoxib 200
mg (P)
PL U/U/U/A
2006 213 161 52 12 Celecoxib 400
mg (P)
PL U/U/U/A
2006 209 157 52 12 Naproxen (P) PL U/U/U/A
Ince 2006 30 15 15 12 Supervised
training (NP)
SC U/U/I/A
Van der Heijde 2006 315 208 107 24 Adalimumab (B) PL A/A/A/A
Van der Heijde 2006 180 155 25 24 Etanercept (B) PL U/U/U/A
2006 175 150 25 24 Etanercept (B) PL U/U/U/A
Lambert 2007 82 38 44 24 Adalimumab (B) PL U/U/A/A
Huang 2008 126 83 43 8 Etanercept (B) PL U/U/U/U
Inman 2008 177 138 39 14 Golimumab (B) PL A/A/A/A
2008 179 149 39 14 Golimumab (B) PL A/A/A/A
Barkham 2010 40 20 20 12 Etanercept (B) PL U/U/A/A
Inman 2010 76 39 37 12 Infliximab (B) PL U/U/U/A
Braun 2011 566 379 187 16 Etanercept (B) AC A/A/A/A
Dougados 2011 82 39 43 12 Etanercept (B) PL U/U/A/I
Navarro-
Sarabia
2011 108 54 54 12 Etanercept (B) AC A/A/A/A
Hu 2012 46 26 20 12 Adalimumab (B) PL U/U/U/I
Bao 2014 213 108 105 24 Golimumab (B) PL U/U/U/A
Huang 2014 344 229 114 12 Adalimumab (B) PL A/A/A/A
*Shown as selection bias (methods for sequence generation and allocation)/performance bias (blinding of participants and personnel)/attrition bias (incomplete
outcome data)/reporting bias (selective outcome reporting). Abbreviations: SSZ sulfasalazine, P pharmacological modalities, PL placebo, NP non-pharmacological
modalities, B biological modalities, SC standard care, AC active comparison, A adequate, U unclear, I inadequate
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Table 2 Outcome matrix





























+,+ (Schober) +,+ (minutes) +,+ (VAS) +,+
(BASDAI question 4)





+,+ (Schober) +,+ (minutes) +,+ (VAS) − +,+ (CRP) −/− −
Physical therapy trials
Kraag (1990) [45] +,+ (TADLQ) +,+
(VAS)
+,+ (Schober) +,+ (TADLQ) − − − −/− −
Hidding (1993)
[46]
+,+ (DFI 0) +,+
(VAS)
+,+ (Schober) +,+ (VAS) +,+ (VAS) +,+
(enthesitis index)
− −/− −
Helliwell [31] − +,+/−
(VAS)










− − +,+ (BAS-G) − − −/− −
Analay (2003) [49] +,+ (BASFI) +,+
(VAS)











+,+ (BASFI) − +,+ (Schober) − − − − −/− −
Lim [30] +,+ (BASFI) +,+/−
(VAS)
+,+ (FFD) − − − − −/− −
Ince (2006) [52] − − +,+ (Schober) − − − − −/− −
Altan (2006) [53] +,+ (BASFI) +,+
(VAS)






+,+ (Schober) +,+ (minutes) − +,+
(enthesitis index)
+,+ (ESR) −/− −




+,+ (VAS) +,+ (VAS) +,+
(enthesitis index)
+,+ (ESR) −/− −
Nissila (1988) [55] − +,+
(VAS)
+,+ (Schober) +,+ (minutes) +,+ (VAS) +,+ (22-joint count) +,+ (CRP) −/− −









+,+ (Schober) +,+ (hours) +,+ (VAS) +,+ (66-joint count) +,+ (ESR) −/− −




+,+ (VAS) − − +,+ (CRP) −/− −
Krajnc (1990) [59] − − +,+ (Schober) − − − −/− −
Taylor [34] − +,+
(VAS)
+,+ (Schober) +,+ (VAS) +,+/− (NRS) +,+/− (joint count) +,+ (CRP) +,+/− SIJ
score
−
Kirwan [29] +,− (HAQ) +,−
(VAS)
+,+ (Schober) +,+/− (VAS) +,– (VAS) +,+/−
(44-joint count)
− −/− −
Clegg (1996) [60] +,+ (DFI) +,+
(VAS)
+,+ (Schober) +,+ (minutes) +,+/− (NRS) +,+ (44-joint count) +,+ (CRP) −/− −
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Table 2 Outcome matrix (Continued)









Altan [35] +,+ (DFI) +,+
(VAS)
+,− (Schober) +,+ (minutes) +,+ (NRS) +,+ (enthesitis
index)
+,+ (CRP) −/− −










+,+ (Schober) +,+ (minutes) +,+ (VAS) +,+ (66-joint count) +,+ (CRP) −/− −
Roychowdhury
(2002) [62]





+,+ (Schober) +,+ (minutes) − +,+
(enthesitis index)
+,+ (CRP) −/− −
Brandt [37] +,+ (BASFI) +,+/−
(NRS)
+,+ (BASMI) +,+/− (NRS) − +,+/−
(66-joint count)
+,+/− (CRP) −/− +,+/−
(NRS)
Davis (2003) [64] +,+ (BASFI) +,+/−
(VAS)
+,+ (Schober) +,+ (minutes) +,+ (VAS) +,– (68-joint count) +,+ (CRP) −/− −
Calin (2004) [65] +,+ (BASFI 0) +,+
(VAS)










− +,+ (minutes) − +,+
(enthesitis index)





+,+ (BASMI) − +,+ (VAS) +,+
(enthesitis Index)















+,+ (BASMI) +,+ (VAS) +,+ (VAS) +,+ (44-joint count) +,+ (CRP) −/− −
Inman (2008) [69] +,+ (BASFI) +,+
(VAS)




+,+ (BASFI) − − +,+ (VAS) − − – −/− −
Inman (2010) [71] +,+ (BASFI) − +,+ (BASMI) − +,+ (BAS-G) − +,+ (CRP) −/− −
Braun (2011) [72] +,+ (BASFI) +,+
(VAS)
+,+ (BASMI) +,+/− (VAS) +,+ (VAS) +,+ (66-joint count) +,+ (CRP) −/− −
Dougados [39] +,+ (BASFI) +,+
(VAS)





+,+ (BASMI) − +,+ (VAS) +,+ (66-joint count) +,+ (CRP) −/− +,+/−
(VAS)
Hu [40] +,+ (BASFI) +,+
(VAS)
− − − − +,+ (CRP) −/− +,+/−
(VAS 0–
10)
Bao (2014) [74] +,+ (BASFI) +,+
(VAS)
+,+ (BASMI) − − − +,+ (CRP) −/− +,+
(JESQ)
Huang (2014) [75] +,+ (BASFI) +,+
(VAS)
+,+ (BASMI) +,+ (VAS) +,+ (VAS) +,+ (44-joint count) +,+ (CRP) −/− –
+,+ indicates that outcome was measured and fully reported
+,+/− indicates that outcome was measured and partially reported (e.g., only the P value is given for the comparison)
+,− indicates that outcome was measured but not reported
− indicates that outcome was not measured
Abbreviations: DFI Dougados functional index, VAS visual analogue scale, NRS numeric range scale, ESR erythrocyte sedimentation rate, CRP C-reactive
protein, BASFI Bath Ankylosing Spondylitis Functional Index, TADLQ Toronto Activity of Daily Living Questionnaire, HAQ Health Assessment
Questionnaire, BASRI Bath Ankylosing Spondylitis Radiology Index, SES Stanford Self-Efficacy Scale, BAS-G Bath Ankylosing Spondylitis Global Index,
BASDAI Bath Ankylosing Disease Activity Index, SPARCC SpondyloArthritis Research Consortium of Canada, JESQ Jenkins Sleep Evaluation Questionnaire
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Table 3 Results of the stratified meta-analyses
Variable No. of trials/comparisons SMD 95% CI I2 Tau2 P for interaction
All trials, physical function 33/43 − 0.50 − 0.61, − 0.40 64% 0.07 –
Fixed-effect model − 0.53 − 0.57, − 0.45
Intervention 0.08 0.42
Pharmacological − 0.53 − 0.64, − 0.42
Non-pharmacological − 0.40 − 0.74, − 0.05
Intervention 0.08 0.44
Biological treatment − 0.57 − 0.68, − 0.46
Other treatment − 0.46 − 0.63, − 0.28
All trials, pain 30/41 − 0.48 − 0.66, − 0.30 87% 0.28 –
Fixed-effect model − 0.50 − 0.56, − 0.44
Intervention 0.19 < 0.001
Pharmacological − 0.64 − 0.78, − 0.49
Non-pharmacological 0.26 − 0.20, 0.72
Intervention 0.29 0.28
Biological treatment − 0.64 − 0.80, − 0-49
Other treatment − 0.41 − 0.68, − 0.14
All trials, spinal mobility 30/45 − 0.32 − 0.48, − 0.17 83% 0.21 –
Fixed-effect model − 0.32 − 0.38, − 0.26
Intervention 0.19 0.28
Pharmacological − 0.35 − 0.51, − 0.19
Non-pharmacological − 0.02 − 0.61, 0.56
Intervention 0.33 0.65
Biological treatment − 0.31 − 0.47, − 0.15
Other treatment − 0.28 − 0.52, − 0.03
All trials, spinal stiffness 25/34 − 0.59 − 0.74, − 0.44 75% 0.14 –
Fixed-effect model − 0.61 − 0.68, − 0.54
Intervention 0.18 0.95
Pharmacological − 0.60 − 0.76, − 0.44
Non-pharmacological − 0.61 − 0.93, − 0.29
Intervention 0.16 0.34
Biological treatment − 0.77 − 0.88, − 0.65
Other treatment − 0.55 − 0.75, − 0.35
All trials, PGA 21/28 − 0.71 − 0.89, − 0.54 83% 0.18 –
Fixed-effect model − 0.74 − 0.81, − 0.67
Intervention 0.19 0.15
Pharmacological − 0.77 − 0.96, − 0.59
Non-pharmacological − 0.37 − 0.81, 0.07
Intervention
Biological treatment − 0.84 − 1.09, − 0.60 0.20 0.23
Other treatment − 0.60 − 0.87, − 0.34
All trials, PJ/E 15/15 0.05 − 0.11, 0.22 68% 0.06 –
Fixed-effect model 0.00 − 0.08, 0.09
Intervention 0.00 < 0.001
Pharmacological − 0.06 − 0.15, 0.03
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between studies (I2 = 75%). The pre-specified strati-
fied analyses did not result in a significant reduction
of τ2, and type of intervention did not seem to be
an important factor to the inconsistency observed
across trials when measuring change in SS in axSpA
trials.
Patient’s global assessment
Twenty-one RCTs reported sufficient data to be in-
cluded in the meta-analysis (28 comparisons, 4031 par-
ticipants). A significantly pooled moderate effect
favoring intervention with large inconsistency was ob-
served, SMD − 0.71 (− 0.89 to − 0.54) and I2 = 83%.
Stratified analyses did result in a significant reduction of
τ2; the type of intervention did not seem to be an
important factor to the inconsistency observed across
trials when measuring change in PGA in axSpA trials.
Peripheral joints and enthesitis index
Fifteen trials (2334 participants) were included in our
meta-analysis. A high between-study heterogeneity was
observed, τ2 = 0.05, with a substantial inconsistency
across studies (I2 = 68%) [13]. There was no significant
difference in the joint count/enthesitis index after the in-
terventions; the overall SMD was 0.05 (− 0.11 to 0.22). A
large reduction in heterogeneity was found in the “type
of intervention variables” (i.e., NP vs. P treatments and B
vs. other treatment [O]), which in turn resulted in sig-
nificant reductions in τ2, supported by statistically sig-
nificant P values for interactions between NP/P and B/O
(P < 0.001 and P = 0.03, respectively). Treatment with a
Table 3 Results of the stratified meta-analyses (Continued)
Variable No. of trials/comparisons SMD 95% CI I2 Tau2 P for interaction
Non-pharmacological 0.99 0.63, 1.35
Intervention 0.04 0.02
Biological treatment − 0.10 − 0.20, − 0.01
Other treatment 0.27 − 0.10, 0.64
All trials, acute phase reactants 27/31 − 0.51 − 0.70, − 0.32 84% 0.22 –
Fixed-effect model − 0.62 − 0.69, − 0.55
Intervention – –
Pharmacological − 0.51 − 0.70, − 0.32
Non-pharmacological – –
Intervention 0.12 0.001
Biological treatment − 0.77 − 1.02, − 0.52
Other treatment − 0.22 − 0.37, − 0.07 −0.07
All trials, spine radiographs 1/1 0.96 0.22, 1.69 – – –






Other treatment 0.96 0.22, 1.69
All trials, fatigue 3/4 − 0.65 − 0.82, − 0.48 0% 0.00 –
Fixed-effect model − 0.65 − 0.82, − 0.48
Intervention – –
Pharmacological − 0.65 − 0.82, − 0.48
Non-pharmacological – –
Intervention – –
Biological treatment − 0.65 − 0.82, −0.48
Other treatment
SMD standardized mean difference, CI confidence interval, I2 inconsistency (i.e., the percentage of total variation across studies due to heterogeneity), Tau2 tau
squared is an estimate of the variance of the true effect sizes, PJ/E peripheral joint count/enthesitis index
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biological agent had a small effect on reducing the num-
ber of swollen joints in axSpA patients, SMD − 0.10 (−
0.20 to − 0.01).
Acute phase reactants
Twenty-seven trials (31 comparisons, 3869 participants)
were included in our meta-analysis. The overall analysis
of change in APRs showed a moderate all-in-all effect
for all interventions in axSpA trials, SMD = − 0.51 (−
0.70 to − 0.32), with a large inconsistency (I2 = 84%). A
large reduction in heterogeneity was found in the “type
of intervention variable” (i.e., B vs. O treatments), which
in turn resulted in a significant reduction in τ2 at 45%,
supported by a statistically significant P value (P = 0.001)
for interaction between B and O treatments. Trials with
a biological intervention had a large effect on reducing
APRs, SMD of − 0.77 (− 1.02 to − 0.52), whereas trials
with other treatment interventions (i.e., NSAIDs, MTX,
SSZ, and NP) had an overall small effect, SMD = − 0.22
(− 0.37 to − 0.07).
Spine/hip radiographs
Only two of the included trials reported a change in
spine radiographs (SR). One trial reported insufficient
data to be included in the meta-analysis. In total, only
one trial with 32 axSpA patients was included in the
analysis. The effect size was 0.96 (0.22 to 1.6), indicating
SSZ did not have an effect on preventing spinal progres-
sion. No trial reported hip radiographs.
Fatigue
Three studies reported sufficient data to be included in
the meta-analysis (4 comparisons, 653 participants). The
overall SMD was − 0.65 (− 0.82 to − 0.48), and no
between-study inconsistency was found (I2 = 0%). The
pre-specified stratified analyses performed with regres-
sion models did not influence the variation in the esti-
mates across strata and were not considered relevant.
Association with primary endpoint
Overall, 27 trials (39 comparisons) stated explicitly what
the primary endpoint measure was and reported the pro-
portion of participants achieving the primary endpoint.
The most commonly composite primary outcome was
the ASAS 20 response criteria (56%) followed by the
change in BASDAI (37%). Two studies (7%) used a cus-
tomized composite outcome (e.g., the overall change in
PGA).
In total, 5723 axSpA patients were included in the
meta-analysis. The pooled OR for achieving primary
endpoint was 3.26 (2.58 to 4.13) in favor of participants
receiving experimental intervention compared to partici-
pants receiving a control comparator.
Univariate meta-regression analyses based on all trials
(i.e., trials that had a measured composite primary end-
point) indicated that a reduction in pain and APRs and
improvements in PF and PGA were significantly associ-
ated with increased odds for achieving primary endpoint,
whereas SM, SS, PJ/E, and fatigue were not (Table 4).
We repeated the meta-regression analysis based on trials
reporting all four domains significantly affecting the OR
for achieving primary endpoint. PF, pain, and PGA were
still significantly associated with the OR for achieving
primary endpoint, whereas APRs proved non-significant.
Multivariable meta-regression analyses showed that PF
did not have a statistically significant explanatory effect
on achieving primary outcome when the following ex-
planatory core outcome domains pain, PGA, and APRs
were added to the model simultaneously. Only reduction
in pain and PGA had a statistically significant effect on
Table 4 Overview of the impact of core outcome domains on the odds ratio (OR) for achieving primary endpoint per trial
Univariate meta-regression analysis
based on trials reporting primary
endpoint
Univariate meta-regression analysis based on trials
reporting all four domains significantly affecting
primary endpoint** (k = 15)
Multivariable meta-regression analysis based
on trials reporting all four domains significantly
affecting primary endpoint** (k = 15)
Domain k OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
Overall* 39 3.26 (2.58, 4.13) < 0.001 3.72 (2.92, 4.74) < 0.001
PF 31 2.79 (1.58, 4.90) 0.001 3.9 (1.67, 9.15) 0.005 0.56 (0.27, 1.16) 0.105
Pain 27 2.11 (1.45, 3.06) < 0.001 5.6 (2.4, 13.15) 0.001 5.19 (2.28, 11.77) 0.001
SM 31 1.20 (0.94, 1.5) 0.142 2.25 (1.27, 3.99) 0.009 1.03 (0.64, 1.68) 0.883
SS 22 1.29 (0.81, 2.06) 0.268 1.88 (0.62, 1.56) 0.227 – –
PGA 20 2.15 (1.41, 3.30) 0.001 2.58 (1.53, 4.34) 0.002 1.87 (1.14, 3.07) 0.018
PJ/E 10 8.14 (0.36, 186.27) 0.161 16.99 (0.00, 3687 0.403 – –
APR 23 1.68 (1.05, 2.68) 0.031 1.61 (0.99, 2.63) 0.054 0.86 (0.58, 1.29) 0.381
SR – – – – – – –
Fatigue 4 2.59 (0.00, 1360) 0.581 – – – –
*Based on trials reporting primary outcome; PF physical function, SM spinal mobility, SS spinal stiffness, APR acute phase reactants, SR spine radiographs
**PF, Pain, PGA, APR
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the OR for achieving primary outcome, regardless of
analysis.
Discussion
This meta-research study aimed to assess the effect of
interventions for axSpA according to each core domain
in the existing ASAS/OMERACT-endorsed core out-
come set. The eligible studies reported data only for pa-
tients with r-axSpA. The most frequent domains
assessed in the included trials were SM and pain, which
are considered prominent features for axSpA [76]. Over-
all outcome reporting was surprisingly good for SM-
ARD/physical therapy trials, especially considering that
most of the included studies were published prior to im-
plementation of the COS.
The overall reporting for the included DC-ART trials
was sparse. Surprisingly, none of the trials measured all
the nine proposed domains. Fifteen (30%) of the in-
cluded studies were published before the COS was sug-
gested by ASAS and endorsed by OMERACT, possibly
explaining the lack of measured domains.
We found that all interventions, both non-
pharmacological and pharmacological, when compared
to control, resulted in an overall statistically signifi-
cant reduction in pain related to axSpA, SS, fatigue,
and APRs and an improvement in PF, SM, and PGA
in axSpA trials. Due to our broad eligibility criteria
where the type of interventions varied greatly among
RCTs, the high between-study heterogeneity observed
was not unexpected. However, type of intervention
did not result in significant change in τ2 for all the
domains. For the domain “PF,” the overall effect size
was moderate regardless of type of intervention. Our
meta-analyses provided evidence that interventions in
axSpA trials did not result in an overall reduction in
swollen peripheral joint count/enthesitis index (PJ/E)
or spinal progression more than placebo. However,
when stratifying on type of interventions, it seemed
that biological treatment had a larger effect on redu-
cing the number of swollen PJ/E. However, one
should be cautious to conclude that biologics are su-
perior to other pharmacologicals for treating inflam-
mation in PJ/E, as our meta-analysis included only a
limited number of trials. Radiographic progression
was measured in only two trials and fully reported in
one. Given that most trials spanned 26 weeks or less,
it is not surprising that they did not measure radio-
graphic progression. MRI is an important imaging
tool to assess axSpA, especially early in the disease
course, before radiographic damage is apparent. Add-
ing magnetic resonance imaging (MRI) to the domain
“spine radiographs” could prove useful, as MRI is
commonly used in short-term axSpA trials [77]. How-
ever, there is currently no consensus on how to
monitor treatment response using MRI modalities in
axSpA patients [78].
For transparency, we believe all domains and instru-
ments used in trials should be reported. We found
that domains and instruments sometimes were used
but not reported separately. For example, the domain
“fatigue,” which is included in the Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI), was
rarely reported separately, whereas the domain “spinal
stiffness,” also included in BASDAI, was reported in
half of all the studies.
As with previous findings, this meta-epidemiological
study found that pain and PGA are important predictors
for treatment responses in axSpA trials [79], thus em-
phasizing the value of reporting core domains separately.
Outcome reporting bias (ORB) can affect the quality
of evidence within a systematic review and meta-analysis
[80]. We found a high suspicion of selective ORB in
eight (16%) of the individual included RCTs. In most
cases, it was not possible to make a clear judgment on
reporting bias due to the lack of published protocols in
this context. Where protocols were available, there was
no evidence of selective reporting. If a composite out-
come (e.g., BASDAI) was reported but no data on any of
the individual core outcome measurements (e.g., fatigue)
were reported, then we judged ORB as low risk; it might
not have been the trialists’ intention to analyze the indi-
vidual core outcomes separately. If a study reported
some of the outcomes from the composite outcome
measurement, then we judged ORB as a high risk, as it
is likely that all the core outcome measurements were
analyzed but some were not reported because of non-
significant results. In many of the individual trials, all of
the outcome domains were not mentioned, thereby re-
quiring clinical judgment to decide whether the outcome
of interest was likely to have been measured for a par-
ticular trial.
A limitation of this study was that we did not contact
the trialists to determine whether outcomes were mea-
sured; many of the studies were published over 15 years
ago, and it would have been difficult to locate the trial-
ists. Another limitation of this study is that our results
are based on axSpA trials included in Cochrane reviews,
and therefore, we did not have control over the literature
searches used. However, Cochrane reviews are known
for the quality of their searches, and we consider the tri-
als included in our study to be representative and our
results to be generalizable. We used the SMDs to meta-
analyze outcomes involving the same or similar con-
structs. We did not include absolute changes and re-
ported in units/percentages of the most common
instruments that the clinicians will understand. How-
ever, SMD is more generalizing and can be interpreted
using a general rule of thumb reported by Cohen, in
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which an SMD of 0.2 represents a small effect, an SMD
of 0.5 represents a medium effect, and an SMD of 0.8 or
larger represents a large effect [12].
Conclusions
Although all types of axSpA conditions were eligible, the
analyses were limited to patients with r-axial SpA (AS),
since none of the eligible studies included patients with
non-radiographic axSpA which could be either be per-
ceived as a limitation or simply a consequence of the
axSpA history reflected in the existing Cochrane reviews.
Consistent outcome reporting for DC-ART trials was
poor. The most responsible core domains for achieving
success in meeting the primary objective per trial were
pain and PGA. Our findings support that PGA and pain
give us a more holistic assessment of disease beyond ob-
jective measures of spinal inflammation.
Outcome reporting bias and “missing data” could be
reduced by implementing the endorsed ASAS/OMER-
ACT COS of outcomes—and thereby improving the pre-
cision of results in meta-analyses.
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